IMU Ann: Clarification Announcement - 3rd May 2022, 1:02pm

[annb0t]

IMU Ann: Clarification Announcement
Price Sensitive: Y
Date: 3rd May 2022, 1:02pm

>>> Read announcement: Google: IMU Market Announcements

 

[Iseki]

So there never was a material agreement with Merk. Thanks for letting us know, (pesky) ASX.

 

[Fact Finder]

This was what was reported when the original announcement was made:

Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial​

Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK).
The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx in combination with Merck’s emerging anti cancer drug, pembrolizumab, in patients with HER-2 positive gastric cancer.
Under the name nextHORIZON, the Phase 2 study will aim to not only evaluate safety, but will look at the duration of patient response, the rate of cancer progression after treatment, overall survival and biomarker evaluation.
Merck promotes pembrolizumab under the brand name KEYTRUDA as a medicine that “may help treat certain cancers by working with your immune system.” The immunotherapy is already approved for use by the FDA.
Last year, the FDA granted accelerated approval for a combination treatment for gastric cancer sufferers comprising Merck’s KEYTRUDA and Genentech’s trastuzumab, a herceptin medication used to treat cancer that is HER-2 receptor positive. Patients who have previously failed on this combination may see good results when switching to Imugene’s vaccine.
Imugene aren’t reinventing the wheel here, they’re making it better. Cancer vaccines like HER-Vaxx have been proven to achieve a greater effect than monoclonal antibody immunotherapies (like trastuzumab) by harnessing the power of the body’s own immune system and training it to display an anti-cancer response.
HER-Vaxx is designed to activate immune cells against tumours that over-express the HER-2/neu receptor, a clinically validated cancer target. This receptor overexpression is common in gastric, breast, ovarian, lung and pancreatic cancers.
Gastric cancers are of particular interest to Imugene due to significant unmet need for targeted treatments. Gastrointestinal cancers are often diagnosed at more advanced stages due to the lack of symptoms in the early stages. The treatment window is relatively small so doctors need specialised and effective treatment options to neutralise the cancer quickly, an option Imugene hopes to give soon.
Managing Director and CEO of the Company, Leslie Chong says “Imugene is excited to announce this collaboration with MSD, one of the world’s leading immuno-oncology companies. HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/ refractory metastatic setting.
“This collaboration with MSD is significant for our company as it provides the opportunity to optimise and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients. We are committed to finding ways to address the unmet needs of patients living with cancer.”
The nextHORIZON trial will be funded by Imugene who as at December 31st 2021 had $118.4 million in cash reserves. Merck will supply their drug for the duration of the study which is expected to run for 24 months, with results expected soon after.
The last six months saw the Company ramp up clinical trials and research which resulted in Imugene posting a higher loss than last year of $14.8 million. The Company did however report revenue of over $5.3 million, up $4.11 million from the prior corresponding period.”

This is what the Clarification said:

SYDNEY, Australia, 3 May 2022:
Pursuant to the Company’s announcement yesterday of MSD’s termination of the supply agreement announced on 15 March 2022, at the request of ASX, Imugene
wishes to provide further clarification having regard to the strict confidentiality covenants of the agreement.

The termination by MSD a tradename of Merck & Co., Inc., Kenilworth, NJ., USA is

not due to:

• The technology;

• Clinical trial design;

• Trial data, as the study has not commenced;

• Safety

The study will continue as planned with alternate supply arrangements available to Imugene, such as direct reimbursement of hospital pharmacies.

There is no material difference to the cost of the trial as budgeted.

There is no material cost to Imugene related to the termination of the agreement”
* * *
Unless you believe that Merck is the most ethical pharmaceutical company on the planet that never does anything purely out of self interest then it is difficult to see what has happened as a signal of some underlying problem with IMU.

It is not for me to remind investors that IMU has multiple partnerships with other pharmaceutical companies all ongoing and multiple platforms and trials and that in one of those trials the participants have had the temerity to keep surviving delaying by months and months the reporting of results to shareholders. I personally hope they continue to annoy the ignorant and impatient.

My opinion only DYOR
FF

AKIDA BALLISTA

 

[Iseki]

This was what was reported when the original announcement was made:

Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial​

Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK).
The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx in combination with Merck’s emerging anti cancer drug, pembrolizumab, in patients with HER-2 positive gastric cancer.
Under the name nextHORIZON, the Phase 2 study will aim to not only evaluate safety, but will look at the duration of patient response, the rate of cancer progression after treatment, overall survival and biomarker evaluation.
Merck promotes pembrolizumab under the brand name KEYTRUDA as a medicine that “may help treat certain cancers by working with your immune system.” The immunotherapy is already approved for use by the FDA.
Last year, the FDA granted accelerated approval for a combination treatment for gastric cancer sufferers comprising Merck’s KEYTRUDA and Genentech’s trastuzumab, a herceptin medication used to treat cancer that is HER-2 receptor positive. Patients who have previously failed on this combination may see good results when switching to Imugene’s vaccine.
Imugene aren’t reinventing the wheel here, they’re making it better. Cancer vaccines like HER-Vaxx have been proven to achieve a greater effect than monoclonal antibody immunotherapies (like trastuzumab) by harnessing the power of the body’s own immune system and training it to display an anti-cancer response.
HER-Vaxx is designed to activate immune cells against tumours that over-express the HER-2/neu receptor, a clinically validated cancer target. This receptor overexpression is common in gastric, breast, ovarian, lung and pancreatic cancers.
Gastric cancers are of particular interest to Imugene due to significant unmet need for targeted treatments. Gastrointestinal cancers are often diagnosed at more advanced stages due to the lack of symptoms in the early stages. The treatment window is relatively small so doctors need specialised and effective treatment options to neutralise the cancer quickly, an option Imugene hopes to give soon.
Managing Director and CEO of the Company, Leslie Chong says “Imugene is excited to announce this collaboration with MSD, one of the world’s leading immuno-oncology companies. HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/ refractory metastatic setting.
“This collaboration with MSD is significant for our company as it provides the opportunity to optimise and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients. We are committed to finding ways to address the unmet needs of patients living with cancer.”
The nextHORIZON trial will be funded by Imugene who as at December 31st 2021 had $118.4 million in cash reserves. Merck will supply their drug for the duration of the study which is expected to run for 24 months, with results expected soon after.
The last six months saw the Company ramp up clinical trials and research which resulted in Imugene posting a higher loss than last year of $14.8 million. The Company did however report revenue of over $5.3 million, up $4.11 million from the prior corresponding period.”

This is what the Clarification said:

SYDNEY, Australia, 3 May 2022:
Pursuant to the Company’s announcement yesterday of MSD’s termination of the supply agreement announced on 15 March 2022, at the request of ASX, Imugene
wishes to provide further clarification having regard to the strict confidentiality covenants of the agreement.

The termination by MSD a tradename of Merck & Co., Inc., Kenilworth, NJ., USA is

not due to:

• The technology;

• Clinical trial design;

• Trial data, as the study has not commenced;

• Safety

The study will continue as planned with alternate supply arrangements available to Imugene, such as direct reimbursement of hospital pharmacies.

There is no material difference to the cost of the trial as budgeted.

There is no material cost to Imugene related to the termination of the agreement”
* * *
Unless you believe that Merck is the most ethical pharmaceutical company on the planet that never does anything purely out of self interest then it is difficult to see what has happened as a signal of some underlying problem with IMU.

It is not for me to remind investors that IMU has multiple partnerships with other pharmaceutical companies all ongoing and multiple platforms and trials and that in one of those trials the participants have had the temerity to keep surviving delaying by months and months the reporting of results to shareholders. I personally hope they continue to annoy the ignorant and impatient.

My opinion only DYOR
FF

AKIDA BALLISTA

No FF. Read the actual ASX announcements.

"Sydney, Australia, 15 March 2022: Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc.,"

Sounds big? You would expect quotes from representatives from both organizations. But there wasn't was there. You know what a verbal is, and here is one here.

You should be helping other investors unpack these oddities, not gloss over them.

Similarly the "agreement announcement with Roche:
Imugene and Roche have entered into a supply agreement for a period of up to five years for the supply of atezolizumab. There is no quote or reference to anyone working at Roche.

Similarly other associated listed entities like CHM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal Nature Cancer.

Well actually no. The article does discuss a CART T therapy targeting CDH1, but not *the* one under development by CHM.

Lets get real. Selling false hope should be called out.

FF, show me where I am wrong. You have the skills.

 

[Fact Finder]

No FF. Read the actual ASX announcements.

"Sydney, Australia, 15 March 2022: Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc.,"

Sounds big? You would expect quotes from representatives from both organizations. But there wasn't was there. You know what a verbal is, and here is one here.

You should be helping other investors unpack these oddities, not gloss over them.

Similarly the "agreement announcement with Roche:
Imugene and Roche have entered into a supply agreement for a period of up to five years for the supply of atezolizumab. There is no quote or reference to anyone working at Roche.

Similarly other associated listed entities like CHM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal Nature Cancer.

Well actually no. The article does discuss a CART T therapy targeting CDH1, but not *the* one under development by CHM.

Lets get real. Selling false hope should be called out.

FF, show me where I am wrong. You have the skills.

I am sorry not sure the point you are making is it that the whole IMU story is a fraud across multinational borders?
FF

 

[Fact Finder]

No FF. Read the actual ASX announcements.

"Sydney, Australia, 15 March 2022: Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc.,"

Sounds big? You would expect quotes from representatives from both organizations. But there wasn't was there. You know what a verbal is, and here is one here.

You should be helping other investors unpack these oddities, not gloss over them.

Similarly the "agreement announcement with Roche:
Imugene and Roche have entered into a supply agreement for a period of up to five years for the supply of atezolizumab. There is no quote or reference to anyone working at Roche.

Similarly other associated listed entities like CHM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal Nature Cancer.

Well actually no. The article does discuss a CART T therapy targeting CDH1, but not *the* one under development by CHM.

Lets get real. Selling false hope should be called out.

FF, show me where I am wrong. You have the skills.

Actually no need to reply report your concerns to the ASIC it’s not my job to convince you that a publicly listed company is not a fraud. I do not have inside information.
Regards
FF

 

[Fact Finder]

No FF. Read the actual ASX announcements.

"Sydney, Australia, 15 March 2022: Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc.,"

Sounds big? You would expect quotes from representatives from both organizations. But there wasn't was there. You know what a verbal is, and here is one here.

You should be helping other investors unpack these oddities, not gloss over them.

Similarly the "agreement announcement with Roche:
Imugene and Roche have entered into a supply agreement for a period of up to five years for the supply of atezolizumab. There is no quote or reference to anyone working at Roche.

Similarly other associated listed entities like CHM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal Nature Cancer.

Well actually no. The article does discuss a CART T therapy targeting CDH1, but not *the* one under development by CHM.

Lets get real. Selling false hope should be called out.

FF, show me where I am wrong. You have the skills.

Actually so that you cannot further attack me for selling false hope which is a very big allegation to make here is the full announcement for completeness:

ASX Announcement
______________________________________________________________________________
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
• New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomas
• nextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab
Sydney, Australia, 15 March 2022: Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer.
nextHERIZON is an open-label, multi-center, signal generating, Phase 2 clinical trial designed to assess the safety and efficacy of HER-vaxx in combination with chemotherapy or pembrolizumab in patients with metastatic HER-2/neu over-expressing gastric or gastroesophageal junction adenocarcinomas who have previously progressed on trastuzumab. The study’s primary endpoints are safety and response rate. Secondary endpoints include duration of response, progression free survival, overall survival, and biomarker evaluation.
“Imugene is excited to announce this collaboration with MSD, one of the world’s leading immuno-oncology companies. HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/refractory metastatic setting,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene. “This collaboration with MSD is significant for our company as it provides the opportunity to optimize and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients. We are committed to finding ways to address the unmet needs of patients living with cancer.”
Effective immediately, under the terms of the agreement, Imugene will be the sponsor of the study and will fund the clinical study from existing budgets and resources. MSD will provide pembrolizumab for the duration of the study. The agreement is for an indefinite term until final reports of the study have been completed, noting that the underlying study is anticipated to run for at least 24 months. The agreement includes customary termination and intellectual property provisions for a clinical collaboration agreement.
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
For more information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

 

[Fact Finder]

Actually no need to reply report your concerns to the ASIC it’s not my job to convince you that a publicly listed company is not a fraud. I do not have inside information.
Regards
FF

You might like to let us know when you have made your complaint so we can follow its progress.
Regards
FF

 

[Iseki]

Actually no need to reply report your concerns to the ASIC it’s not my job to convince you that a publicly listed company is not a fraud. I do not have inside information.
Regards
FF

Imugene MD & CEO Leslie Chong said: “Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries.

Well no. City of Hope were granted the patent. Maybe they photocopied it and sent IMU a copy...

Here's the thing, and I won't waste any more of your time: If the ASX announcements are shonky and deceptive then their science is as well.

 

[Fact Finder]

Imugene MD & CEO Leslie Chong said: “Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries.

Well no. City of Hope were granted the patent. Maybe they photocopied it and sent IMU a copy...

Here's the thing, and I won't waste any more of your time: If the ASX announcements are shonky and deceptive then their science is as well.

You have not wasted my time but your preparedness to attack me, state IMU is a fraud and then not have the courage of your conviction to take your concerns to ASIC when all it requires is filling out a form on line says a great deal and it is not about me or IMU or Professor Yuman Fong and the City of Hope.

You are clearly someone who likes to rant when things do not go your way and blame everyone else for your inadequacies.

Regards
FF

 

[Iseki]

You have not wasted my time but your preparedness to attack me, state IMU is a fraud and then not have the courage of your conviction to take your concerns to ASIC when all it requires is filling out a form on line says a great deal and it is not about me or IMU or Professor Yuman Fong and the City of Hope.

You are clearly someone who likes to rant when things do not go your way and blame everyone else for your inadequacies.

Regards
FF

Never attacked you, only IMU for its selling false hope to bolster its share price.

I don't need to go to ASIC.

You haven't even defended why IMU makes announcements about collaborations with huge well known pharma companies yet won't provide any quote from anyone at those companies.

You haven't defended why the CEO glosses over the recipient of patents.

My point is not one for ASIC but to the investors: If IMU fib about little things like these then they will fib about the science, and their patients will have suffered needlessly.

You once posted that medical ethics is complicated. Maybe just start with Hippocrates.

 

[Fact Finder]

Never attacked you, only IMU for its selling false hope to bolster its share price.

I don't need to go to ASIC.

You haven't even defended why IMU makes announcements about collaborations with huge well known pharma companies yet won't provide any quote from anyone at those companies.

You haven't defended why the CEO glosses over the recipient of patents.

My point is not one for ASIC but to the investors: If IMU fib about little things like these then they will fib about the science, and their patients will have suffered needlessly.

You once posted that medical ethics is complicated. Maybe just start with Hippocrates.

You are saying IMU are lying to the ASX and investors. Companies do not fib. Children fib.

If a company has lied this is a very serious criminal offence and you either believe they have lied or you do not there is no grey.

I do not believe they have lied. If you do then report it to ASIC in a simple online form.

If you do not think you attacked me and I think you did it is for others to judge.

If you had any knowledge of who Professor Yuman Fong is you would not make these sort of allegations.

They are a disgusting undeserved slur on his character.

There are many other great people beyond Leslie Chong who you have labeled as liars and will not back up your wild claims with a simple ASIC complaint.

At best your statements are cowardly at worst something more sinister.

FF

 

[Iseki]

You are saying IMU are lying to the ASX and investors. Companies do not fib. Children fib.

If a company has lied this is a very serious criminal offence and you either believe they have lied or you do not there is no grey.

I do not believe they have lied. If you do then report it to ASIC in a simple online form.

If you do not think you attacked me and I think you did it is for others to judge.

If you had any knowledge of who Professor Yuman Fong is you would not make these sort of allegations.

They are a disgusting undeserved slur on his character.

There are many other great people beyond Leslie Chong who you have labeled as liars and will not back up your wild claims with a simple ASIC complaint.

At best your statements are cowardly at worst something more sinister.

FF

I think you'll find it is the ASX that is accusing IMU of lying by omission, hence the oft repeated phrase in their announcements: "at the request of ASX, Imugene wishes to provide..."

I have merely highlighted some anomalies that I find disconcerting, none of which you care to address.

Lastly, let me assure you that there is nothing cowardly about coming forward and saying I don't like these things about their announcements, I didn't like them at the time, and they have come back to bite.

Maybe we give it a rest now?

 

[Fact Finder]

Calling people the calibre of Professor Yuman Fong a liar behind an anonymous identity on social media is cowardly no matter how anyone looks at it.

If you believed what you were saying you would out yourself publicly and bring a complainant to ASIC.

You have now turned from saying people are lying to some never heard of before definition that if the ASX asks for more information from a company the company must have lied in the original notice.

I asked you for more information about your first post therefore by your definition your first post contained lies authored by you.

I will leave it now because you are here without conviction and without evidence.

FF.

 

[em1389]

I'm not concerned about where IMU is currently trading, the trial results speak for themselves and regardless of how they word their announcements I am proud to be a holder.

@Iseki we are all entitled to our views, however @Fact Finder is correct in saying you calling people out to be liars is cowardly.

I understand it can be frustrating at times when the share price isn't where you thought it will be but coming on here calling people liars is not the right approach.

 

[Iseki]

Calling people the calibre of Professor Yuman Fong a liar behind an anonymous identity on social media is cowardly no matter how anyone looks at it.

If you believed what you were saying you would out yourself publicly and bring a complainant to ASIC.

You have now turned from saying people are lying to some never heard of before definition that if the ASX asks for more information from a company the company must have lied in the original notice.

I asked you for more information about your first post therefore by your definition your first post contained lies authored by you.

I will leave it now because you are here without conviction and without evidence.

FF.

I never mentioned Professor Yuman Fong. Why do you imagine I have?
FF everyone wants to cure cancer but there is little to recommend the authors or authorizers of the company announcements.

 

[Iseki]

I'm not concerned about where IMU is currently trading, the trial results speak for themselves and regardless of how they word their announcements I am proud to be a holder.

@Iseki we are all entitled to our views, however @Fact Finder is correct in saying you calling people out to be liars is cowardly.

I understand it can be frustrating at times when the share price isn't where you thought it will be but coming on here calling people liars is not the right approach.

It's good to be proud of your investments, but never be bullied into not questioning something that doesn't seem right. Remember the CEO and Chairman aren't medically qualified so perhaps they too are running on pride and hope.

 

[em1389]

It's good to be proud of your investments, but never be bullied into not questioning something that doesn't seem right. Remember the CEO and Chairman aren't medically qualified so perhaps they too are running on pride and hope.

It’s not about being bullied. I think it comes down to how you relay your message, a little thought before powering away on the keyboard can go a long way.

 

[Iseki]

It’s not about being bullied. I think it comes down to how you relay your message, a little thought before powering away on the keyboard can go a long way.

Fair enough. I sold out of IMU a long time ago but I worry that things ( maybe just little things) aren't quite right. I really only wanted to point this out to users here who have done a brilliant job in researching other stocks, who have contributed tirelessly for the benefit of others (me included) but who might have a blind spot here and would be exposed. I would love IMU to cure some cancers, and even if they don't their share price can grow and progress made. But more realistically I would like to see cancer cured by anyone, and my friends here, most notably FF, not be at risk.

 

[em1389]

Fair enough. I sold out of IMU a long time ago but I worry that things ( maybe just little things) aren't quite right. I really only wanted to point this out to users here who have done a brilliant job in researching other stocks, who have contributed tirelessly for the benefit of others (me included) but who might have a blind spot here and would be exposed. I would love IMU to cure some cancers, and even if they don't their share price can grow and progress made. But more realistically I would like to see cancer cured by anyone, and my friends here, most notably FF, not be at risk.

I completely understand. We all invest at our own risk and it is on each of us to do our own research. I admire @Fact Finder amongst others in the BRN thread and appreciate the effort they go to. If you think they may be blind to a fact there is polite way to raise it, I know from the other thread that you can, your posts in this thread though came across as quite passive aggressive and insinuated employees at IMU are liars. This response was much more relatable than your previous post which came across in the wrong light.

I’m in my early thirties and have lost a more than a handful of friends and family to cancer, so am quite heavily invested knowing that what we have here is life changing. Personally I’m impressed with the trial results announced to date and am happy to ride this out.